{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:24:16Z","timestamp":1778261056747,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1996,12,1]],"date-time":"1996-12-01T00:00:00Z","timestamp":849398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[1996,12]]},"DOI":"10.1016\/s0952-7915(96)80018-5","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T10:37:07Z","timestamp":1027593427000},"page":"872-877","source":"Crossref","is-referenced-by-count":95,"title":["Cytokines in autoimmunity"],"prefix":"10.1016","volume":"8","author":[{"given":"Fionula M","family":"Brennan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0952-7915(96)80018-5_BIB1","author":"Brennan","year":"1996"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB3","first-page":"225","article-title":"Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-\u03b1 antibody with the IL-1 receptor antagonist","volume":"6","author":"Butler","year":"1995","journal-title":"Eur Cytokine Network"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB4","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/eji.1830250647","article-title":"The type 1 interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice","volume":"25","author":"Probert","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal antibody to tumour necrosis factor \u03b1 (cA2) in patients with rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB7_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/rheumatology\/34.4.334","article-title":"The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis","volume":"34","author":"Rankin","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB8","first-page":"295","article-title":"Soluble tumor necrosis factor receptor (sTNFR):-results of a phase I dose-escalation study in patients with rheumatoid arthritis [abstract]","volume":"32","author":"Moreland","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB9_1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/art.1780390703","article-title":"Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor \u03b1 antibody in rheumatoid arthritis","volume":"7","author":"Paleolog","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor \u03b1 monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","article-title":"Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis","volume":"94","author":"Cope","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB12","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1002\/eji.1830251207","article-title":"Role of tumor necrosis factor-alpha in the regulation of activated synovial T cell growth: down-regulation of synovial T cells in rheumatoid arthritis patients","volume":"25","author":"Lai","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-065X.1995.tb00070.x","article-title":"Monoclonal anti-TNF\u03b1 antibody as a probe of pathogenesis and therapy of rheumatoid disease","volume":"144","author":"Maini","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB14_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"Van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm0395-211","article-title":"Multiple sclerosis: TNF revisited, with promise [comment]","volume":"1","author":"Raine","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB16_1","doi-asserted-by":"crossref","first-page":"11294","DOI":"10.1073\/pnas.92.24.11294","article-title":"Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha","volume":"92","author":"Probert","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nm0395-244","article-title":"The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis","volume":"1","author":"Sommer","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB18","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1073\/pnas.92.8.3601","article-title":"Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor","volume":"92","author":"Genain","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB19","first-page":"625","article-title":"An open study of pentoxifyline in the treatment of severe refractory rheumatoid arthritis","volume":"22","author":"Maksymowych","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/370558a0","article-title":"Regulation of tumour necrosis factor a processing by a metalloproteinase inhibitor","volume":"370","author":"McGeehan","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/370218a0","article-title":"Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing","volume":"370","author":"Mohler","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/370555a0","article-title":"Processing of tumour necrosis factor-\u03b1 precursor by metalloproteinases","volume":"370","author":"Gearing","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.181.3.1205","article-title":"A metalloprotease inhibitor blocks shedding of the 80 kD TNF receptor and TNF processing in T lymphocytes","volume":"181","author":"Crowe","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB24_1","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1172\/JCI118739","article-title":"Paradoxical effects of a synthetic metalloproteinase inhibitor which blocks both p55 and p75 TNF receptor shedding and TNF\u03b1 processing","volume":"97","author":"Williams","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-3083.1995.tb03639.x","article-title":"TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action","volume":"42","author":"Brennan","year":"1995","journal-title":"Scand J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB26","first-page":"86","article-title":"Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice","volume":"46","author":"Georgopoulos","year":"1996","journal-title":"J Inflamm"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB27","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/art.1780390704","article-title":"The IL-1ra Arthritis Study Group: Dose-range and dose frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis","volume":"39","author":"Campion","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.1780390212","article-title":"Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis","volume":"39","author":"Drevlow","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice: a comparative study using anti-TNF alpha, anti-IL-1 alpha\/beta, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/cyto.1996.0052","article-title":"Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice","volume":"8","author":"Ku","year":"1996","journal-title":"Cytokine"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/art.1780370507","article-title":"Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis","volume":"37","author":"Firestein","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB32","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.1780371114","article-title":"In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis. Sjogren's syndrome, and systemic lupus erythematosus","volume":"37","author":"Llorente","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB33","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1084\/jem.179.5.1517","article-title":"Immunoregulatory role of interleukin 10 (IL-10) in rheumatoid arthritis","volume":"179","author":"Katsikis","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/art.1780380115","article-title":"Elevated interleukin-10 levels in patients with rheumatoid arthritis","volume":"38","author":"Cush","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/art.1780380805","article-title":"Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis","volume":"38","author":"Chomarat","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/art.1780390516","article-title":"Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4","volume":"39","author":"Vanroon","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB37","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.1780381210","article-title":"Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10","volume":"38","author":"Perez","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB38_1","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1172\/JCI117993","article-title":"Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis","volume":"95","author":"Kasama","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/art.1780390318","article-title":"Interleukin-10 inhibition of the progression of established collagen-induced arthritis","volume":"39","author":"Walmsley","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB40_1","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1002\/eji.1830251108","article-title":"Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10","volume":"25","author":"Crisi","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB41_1","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.4049\/jimmunol.154.12.6634","article-title":"Curative and protective effects of IL-10 in experimental autoimmune thyroiditis (EAT). Evidence for IL-10-enhanced cell death in EAT","volume":"154","author":"Mignon-Godefroy","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"Kuhn","year":"1993","journal-title":"Cell"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.1780390305","article-title":"Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood","volume":"39","author":"Hagiwara","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.179.1.305","article-title":"Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB\/W F1 mice","volume":"179","author":"Ishida","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1084\/jem.178.1.175","article-title":"Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans","volume":"178","author":"Wogensen","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1084\/jem.179.4.1379","article-title":"Production of interleukin-10 by islet cells accelerates immune-mediated destruction of \u03b2 cells in nonobese diabetic mice","volume":"179","author":"Wogensen","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/cyto.1996.0054","article-title":"Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment","volume":"8","author":"Nicoletti","year":"1996","journal-title":"Cytokine"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-5728(95)00070-I","article-title":"Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients","volume":"61","author":"Porrini","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB49","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.4049\/jimmunol.156.10.3583","article-title":"\u201cThe good, the bad, and the ugly\u201d: the role of chemokines in models of human disease - commentary","volume":"156","author":"Strieter","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB50_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jlb.59.1.6","article-title":"The role of chemokines in inflammatory joint disease","volume":"59","author":"Kunkel","year":"1996","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB51","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.4049\/jimmunol.156.8.3017","article-title":"Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat","volume":"156","author":"Berman","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB52","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.4049\/jimmunol.155.10.5003","article-title":"An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis","volume":"155","author":"Karpus","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB53_1","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1073\/pnas.92.11.4823","article-title":"Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA\/1 mice","volume":"92","author":"Germann","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/eji.1830260129","article-title":"High doses of interleukin-12 inhibit the development of joint disease in DBA\/1 mice immunized with type II collagen in complete Freund's adjuvant","volume":"26","author":"Hess","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/0167-5699(96)30011-X","article-title":"IL-12: a key cytokine in immune regulation","volume":"17","author":"Lamont","year":"1996","journal-title":"Immunol Today"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1084\/jem.181.1.381","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12","volume":"181","author":"Leonard","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB57","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB58_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0167-5699(95)80006-9","article-title":"The role of IL-12 in the induction of organ-specific autoimmune diseases","volume":"16","author":"Trembleau","year":"1995","journal-title":"Immunol Today"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB59","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4049\/jimmunol.156.3.1315","article-title":"Cytokine gene expression in islets and thyroids of BB rats \u2014 IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats","volume":"156","author":"Zipris","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00400422","article-title":"Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice","volume":"39","author":"Rothe","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB61_1","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1084\/jem.182.6.1985","article-title":"Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple scierosis lesions","volume":"182","author":"Windhagen","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB62","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1074-7613(00)80413-6","article-title":"IL-12 deficient mice are defective in IFN\u03b3 production and type 1 cytokine responses","volume":"4","author":"Magram","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/S0952-7915(96)80018-5_BIB63_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.156.1.5","article-title":"Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalolmyelitis (EAE)","volume":"156","author":"Ferber","year":"1996","journal-title":"J Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791596800185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791596800185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T17:45:45Z","timestamp":1680803145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791596800185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,12]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1996,12]]}},"alternative-id":["S0952791596800185"],"URL":"https:\/\/doi.org\/10.1016\/s0952-7915(96)80018-5","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[1996,12]]}}}